News21/10/2026
NewLimit reports manufacturing and preclinical development progress
NewLimit, Inc. →NewLimit reported scaling manufacturing for its liver-directed LNP-RNA program and conducting large-animal studies. It also announced new clinical-development and technical-operations leaders. Human trials were planned for the following year, rather than reported as underway.